Malaria and curable sexually transmitted infections in pregnant women: A two-years observational study in rural Burkina Faso

Serge Henri Zango, Moussa Lingani, Innocent Valea, Sékou Samadoulougou, Biebo Bihoun, Toussaint Rouamba, Karim Derra, Eli Rouamba, Phillipe Donnen, Michele Dramaix, Halidou Tinto, Annie Robert

1 Pôle d’Épidémiologie et biostatistique, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgique, 2 Institut de Recherche en Sciences de la Santé, Direction Régionale du Centre Ouest (IRSS/DRCO), Bobo-Dioulasso, Burkina Faso, 3 Centre MURAZ, Institut National de Santé Publique (INS), Bobo-Dioulasso, Burkina Faso, 4 École de santé publique, Université Libre de Bruxelles, Bruxelles, Belgique

* henrizango@yahoo.fr, serge.zango@uclouvain.be

Abstract

Background

Malaria and curable sexually transmitted infections (STI) are the most common curable infections known to have a severe impact on pregnancy outcomes in sub-Saharan Africa. This study aims to assess the marginal and joint prevalence of symptomatic cases of malaria and STI in pregnant women living in rural settings of Burkina Faso and their associated factors, after more than a decade of the introduction of intermittent preventive treatment (IPT-SP).

Methods

We carried out an observational study in two health districts in rural Burkina, namely Nanoro and Yako. Routine data were collected during antenatal and delivery visits for all women who delivered in the year 2016 and 2017. Logistic regression models were used to assess factors associated with infections.

Results

We collected data from 31639 pregnant women attending health facilities. Malaria, curable STI and their coinfections were diagnosed in 7747 (24.5%; 95%CI: 24.0–25.0%), 1269 (4.0%; 95%CI: 3.8–4.2%) and 388 (1.2%; 95%CI: 1.1–1.4%) women, respectively. In multivariate logistic regression, malaria occurrence was significantly higher in pregnant women < 20 years (Adjusted OR = 2.36; 95% CI: 2.07–2.69) than in women ≥ 30 years. The prevalence of curable STI was also significantly higher in students (Adjusted OR = 1.93; 95% CI: 1.26–2.95) and compensated workers (Adjusted OR = 1.52; 95% CI: 1.01–2.17) than in uncompensated workers. Women who received no IPT-SP had higher prevalence of malaria (Adjusted OR = 3.33; 95%CI: 3.00–3.70), curable STI (Adjusted OR = 1.96 95%CI: 1.67–2.30), and malaria and STI coinfections (Adjusted OR = 3.28; 95%CI: 2.89–3.72).
1.60–2.39) and co-infections (Adjusted OR = 2.11; 95% CI: 1.50–2.95) compared to women who received SP.

**Conclusion**

Malaria and curable STI remain highly prevalent in rural settings of Burkina Faso, with young pregnant women and women who received no IPT-SP being the most affected. Prevention must be reinforced to improve maternal and infant health.

**Introduction**

Malaria and curable sexually transmitted infections (STI), namely syphilis, gonorrhea, trichomoniasis, and chlamydia are the most common curable infections responsible for poor outcomes of pregnancy in sub-Saharan Africa [1,2]. These adverse outcomes include low birth weight, prematurity, stillbirth, and miscarriages [3–7]. In Burkina Faso, as in most of sub-Saharan countries, two main interventions are implemented to prevent malaria in pregnant women: long-lasting insecticide-treated nets to prevent the biting of the *Anopheles* mosquitoes, and intermittent preventive treatment with sulfadoxine-pyrimethamine (IPT-SP) according to recommendations from the World Health Organisation (WHO) [8,9]. Also, effective management of malaria cases detected during antenatal visits with a rapid diagnostic test (RDT) or blood smear microscopy and effective treatment with the artemisinin-based combination could contribute to reducing the burden of malaria [10]. Nevertheless, many cases of malaria are not managed due to the low performance of different malaria diagnostic methods. Indeed, authors report that the *Plasmodium* lactate dehydrogenase-based RDT (widely used in the routine) and microscopy have a low sensitivity: 54.8% (48–62%) and 54.2% (47–61%) respectively, but a good specificity: 97.9% (95–99%) and 98.3% (95–100%) respectively, when compared to polymerase chain reaction as reference test [11]. Case management of STI in pregnant women is the main strategy to reduce their impact on birth outcomes in Burkina Faso. However, among various curable STIs, only syphilis is systematically screened in pregnant women using a rapid diagnostic test. The other STIs are clinically diagnosed and treated during the antenatal visit [12]. The use of syndromic management as a diagnostic method for curable STIs in the routine care remains widely known as an insufficient diagnostic method with a low sensitivity (30–80%) and specificity (40–80%) for gonorrhea and chlamydia and trichomoniasis among pregnant women [13–15]. So, the majority of curable STIs are not clinically diagnosed.

Information on cases are routinely collected in the health system information. In 2006, when the IPT-SP strategy was adopted, some authors reported malaria incidence rate at 39.2 per 1,000 pregnant women-months in the rural health facilities of Boucle du Mouhoun region in Burkina Faso [16]. In 2014, just before the revision of the strategy from two doses to at least three doses of IPT-SP during pregnancy, the prevalence of malaria was 27% in pregnant women in Nanoro, Burkina Faso [9]. Since 2003 with a reported seroprevalence of syphilis of 1.7% [17], only the prevalence of *Trichomonas vaginalis* (13%) in teenage pregnant women was published among curable STI in pregnant women population in rural setting of Burkina Faso [18]. We herein report the results of an observational study carried out in the hand-recorded registries of two health districts in rural Burkina Faso, namely Nanoro and Yako. We aimed to provide estimates of the health facility-based prevalence of symptomatic malaria and curable STI detected by symptoms in pregnant women and associated maternal characteristics. Malaria and curable STI co-infections were also explored in these rural settings.
Materials and methods

Study area

The study was carried out in both Nanoro health district (NHD) and Yako health district (YHD) which are neighboring health districts, with NHD in the south of YHD (Fig 1). In 2016, both districts had 77 health facilities covering a total population of 580,279 inhabitants, 166,683 in NHD, and 413,596 in YHD. The number of expected pregnancies based on national annual statistics was 8957 and 22032 in NHD and YHD, respectively. So, the total expected number of pregnancies was 30989 [19]. In this area, malaria transmission is highly seasonal and overlaps with the rainy season that lasts from July to December [20].

Study design and data collection

We conducted a retrospective study in 61 out of 77 health facilities belonging to NHD and YHD. Sixteen health facilities were excluded because they were too far or because of a lack of
hand-recorded registries. In the routine health system, data of pregnant women must be collected in hand-recorded registries by the nurses and midwives during the antenatal care visits and at delivery visits.

**Study population**

We considered data from all women who delivered between January 2016 and December 2017 in this study. The data of ANC visits performed in 2015 for women who delivered at the beginning of 2016 were also considered. The data were captured retrospectively during the last trimester of 2018 in electronic pads using the REDCap application.

**Definition of terms**

In rural health settings, the diagnosis of malaria and that of STI are performed according to the national guidelines. Based on clinical signs or history of fever, all suspected cases of malaria in pregnant women are investigated by using malaria RDT or a microscopy examination. The confirmed cases of uncomplicated malaria are treated with artemisinin-based combination (artemether-lumefantrine or artesunate-amodiaquine), or quinine. Also, all malaria cases diagnosed in surveys in the area are transferred to health facilities for the treatment. A systematic screening of syphilis is performed for all pregnant women at their first ANC visit. The diagnostic of other curable STI is carried out using clinical syndrome-based algorithms as recommended by the WHO for the constrained resource setting [21]. The marginal prevalence of malaria or curable STI is the proportion of women infected by each type of infection among women attending the health facilities. The joint prevalence is the proportion of the co-infections of both malaria and curable STI. We defined co-infection as the occurrence of both malaria and curable STI in a pregnant woman during the same pregnancy. Student means that the pregnant woman was continuing secondary or higher education. Women with compensated work means that the pregnant women had an outdoor remunerative activity (civil servant, market vendor, hairdresser). Women with uncompensated work are usually farmers who produce for family consumption. Primigravidae means that the women were in their first pregnancy, secundigravidae for those that were in their second pregnancy, and multigravidae were used for women in their third pregnancy or more. The history of miscarriage was defined as a fetal death before 28.0 weeks of gestation that occurred in a prior pregnancy. The history of stillbirth was defined as delivery of a new-born with no signs of life between 28.0 and 37.0 weeks of gestation in a prior pregnancy. Female genital mutilation (FGM) was defined as partial or total removal of the external female genitalia.

**Statistical analysis**

All analyses were performed with Stata® version 15.1. The statistical significance level was set to 0.05. We included all women having at least one visit in the period to compute prevalence. Cochran-Armitage test was used to assess the trends in the prevalence of malaria, curable STI, and co-infection by year. Complete cases mean all cases not having missing data for the covariates used in the models. Univariate and multivariate logistic regressions were performed to identify factors associated with malaria and STIs. Before performing multivariate regression analysis, correlation coefficients were checked for multicollinearity, and variance inflation factors were used for eliminating a covariate if greater than 10. Only factors associated (with a p-value < 0.05) with at least one of them in the univariate logistic regression analysis were considered in multivariate regression. Odds ratio and adjusted odds ratio are reported with their 95% confidence intervals.
Ethical considerations

Ethical approval for this study was obtained from both the « Comité d'Ethique Hospitalo-Facultaire Saint-Luc UCLouvain » in Belgium and the National Ethics Committee (Comité d’Ethique pour la Recherche en Santé, CERS) in Burkina Faso. The identities of all patients were anonymized during the data capture.

Results

Overall, data from 31639 pregnant women were collected in 61 health facilities (Fig 1). The number of women with missing delivery visit was 2729 (8.6%) (Fig 2). The mean age of women was 25.6 years, including 19.8% of teenagers, 94.6% of them were women with uncompensated work and 2.2% were students. Multigravidae were more represented (44.9%) (Table 1). Sixty-two pregnant women (0.2%) were HIV seropositive.

Between August 2015 to December 2017, symptomatic malaria, curable STI detected by symptoms and co-infections were diagnosed in 7747 (24.5%; 95%CI: 24.0–25.0%), 1269 (4.0%; 95%CI: 3.8–4.2%) and 388 (1.2%; 95%CI: 1.1–1.4%) pregnant women, respectively. Among women having experienced malaria, 960 (3.0%; 95%CI: 2.9–3.2%) and 197 (0.6%; 95%CI: 0.5–0.7%) had two and three episodes, respectively. Two episodes of curable STI were reported in 154 (0.5%; 95%CI: 0.4–0.6%) pregnant women. Table 2 describes prevalence of these infections and shows an increase from 2015 to 2017 in prevalence of symptomatic malaria, curable STI detected by symptoms, and of co-infections.

Table 3 reports the univariate and multivariate associations of women characteristics with malaria. The prevalence of symptomatic malaria significantly decreased with the age of the pregnant women. It was also significantly higher in the students (Adjusted OR = 1.38; 95% CI: 1.06–1.79) than in women with uncompensated work, after adjusting to other covariates.

The prevalence of symptomatic malaria was significantly higher in primigravidae and secundigravidae than in multigravidae in univariate analysis, but these associations did not remain in multivariate analysis. Women who received no IPT-SP experienced significantly more malaria compared to women who received IPT-SP (Adjusted OR = 3.32; 95% CI: 2.96–3.74).

All variance inflation factors were lower than 10, so no multicollinearity was observed; the greater correlation was +0.27 (variance inflation factors = 1.1), corresponding to a positive association between age and gravidity, a mark of reliability.

History of miscarriage, stillbirth, or FGM was not associated with malaria infections in univariate regression.

Table 4 reports univariate and multivariate associations of women characteristics with curable STI detected by symptoms. Curable STI prevalence was higher in pregnant women aged <20 years than in women aged over 30 years in univariate analysis but this association did not remain in multivariate. Both women with compensated work and students experienced more curable STI than women with uncompensated work in univariate and multivariate analysis. Women having an FGM significantly experienced less curable STI and the reduced prevalence remained after adjustment (Adjusted OR = 0.76; 95%CI: 0.64–0.90). Women who received no IPT-SP experienced more STI than women who received IPT-SP (Adjusted OR = 1.96; 95%CI: 1.60–2.39).

A similar association was found in women with coinfection malaria and STI (Adjusted OR = 2.11; 95%CI: 1.50–2.95) (Fig 3).

Discussion

The current study aimed to estimate the prevalence of symptomatic malaria and curable STI detected by symptoms in pregnant women attending rural health facilities. Information were
captured retrospectively from routine data collected in a rural setting. Comparison between distributions in both available data and complete case data shows that there is no bias to use complete case data for analysis. Health facilities included in our study cover the entire study area, and a half (51%) of the number of pregnancies expected for the two-years period of deliveries. Also, the high proportion of multigravidae and women with compensated work are in concordance with rural women characteristics in Burkina Faso, reinforcing the representativity of the sample [19].
The results showed that the prevalence of symptomatic malaria between 2015 and 2017 in pregnant women was lower than reported in 2014 in Nanoro (27%) [9], or 2006 [16]. Our study used mainly symptomatic cases of malaria diagnosed during antenatal visits and some malaria cases (asymptomatic or symptomatic) screened in clinical studies or surveys in the

Table 1. General characteristics of the study population.

| Available data | Complete cases (n = 17826) |
|----------------|---------------------------|
| **n** |
| Mean ± SD | % | Mean ± SD | % |
| Age at entry (years) | 26672 | 25.4 ± 6.3 | 20.9 | 19.8 |
| < 20 | 51.9 | 27.2 | 28.2 |
| 20 to 29 | | | |
| ≥ 30 | | | |
| Occupation | 28539 | 94.2 | 94.6 |
| Uncompensated workers | | | |
| Student | 2.2 | 2.0 |
| Compensated workers | 3.6 | 3.4 |
| Married | 23605 | 98.2 | 98.5 |
| Yes | 1.8 | 1.5 |
| No | | | |
| Gravidity | 27678 | 22.7 | 21.8 |
| Primigravidae | 33.6 | 33.3 |
| Secundigravidae | 43.7 | 44.9 |
| Multigravidae | | | |
| History of miscarriage | 29801 | 2.0 | 2.2 |
| Yes | 98.0 | 97.8 |
| No | | | |
| History of stillbirth | 29801 | 0.5 | 0.6 |
| Yes | 99.5 | 99.4 |
| No | | | |
| Female genital mutilation | 29801 | 42.1 | 46.6 |
| Yes | 57.9 | 53.4 |
| No | | | |
| IPT-SP \[a\] | 20861 | 14.2 | 11.8 |
| Yes | 86.8 | 88.0 |
| No | | | |

\[a\] IPT-SP: Intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women.

Table 2. Health facility-based prevalence of symptomatic malaria and curable STI.

| Prevalences (%) |
|-----------------|
| **Overall** | 2015 | 2016 | 2017 | Cochran X² P-value |
| N = 31639 | N = 5758 | N = 15832 | N = 10049 |
| Malaria | 24.5 | 21.4 | 21.9 | 30.4 | <0.001 |
| STI \[\text{a}\] | 4.0 | 3.3 | 3.5 | 5.2 | <0.001 |
| Co-infections \[\text{b}\] | 1.2 | 0.9 | 1.1 | 1.6 | <0.001 |

\[\text{a}\] STI: Sexually transmitted infections.

\[\text{b}\] Cases included in both previous lines.

https://doi.org/10.1371/journal.pone.0242368.t001

https://doi.org/10.1371/journal.pone.0242368.t002
area and transferred to the health facilities. In addition, this lower prevalence could also be explained by the reinforcement in malaria prevention in pregnant women by the introduction of two doses of sulfadoxine-pyrimethamine in 2006, and the increase to at least three doses in 2014 in Burkina Faso [9]. However, malaria prevalence increased significantly from 2015 to 2017. This increase in the health facility-based prevalence of malaria in these last years has also been reported by the WHO African region [22]. In Burkina Faso, a full free maternal healthcare was implemented in 2016 in all public healthcare facilities, and the numbers of health facilities and health providers were increased [19]. This context improved the access to healthcare and increased health facilities attending that could explain the high report of diseases in health facilities. In our study, the prevalence of curable STI in pregnancy detected by symptoms was lower than the one reported for globally sub-Saharan Africa that was estimated at least 15% [3]. Many reasons could explain this low prevalence in pregnant women population in our country. Beyond the medium sensitivity and specificity of syndromic-based to diagnose gonococcal and chlamydia infections [23–25], the use of azithromycin in mass drug administration in the general population through implementation of trachoma control

| Table 3. Factors associated with malarial infection in univariate and multivariate logistic regression analyses in pregnant women. |
|--------------------------------------------------|-------------------|------------------|------------------|
| Age (years)                                      | n                | Malaria % | OR (95%CI) | Adj OR (95%CI) |
| < 20                                             | 3524             | 20.2     | 2.62 (2.31–2.98)** | 2.36 (2.07–2.69)** |
| 20 to 29                                         | 9279             | 13.2     | 1.58 (1.41–1.77)** | 1.53 (1.36–1.71)** |
| ≥30                                              | 5023             | 8.8      | 1.00         | 1.00            |
| Occupation                                       |                  |          |             |                 |
| Students                                         | 362              | 22.9     | 1.97 (1.54–2.53)** | 1.38 (1.06–1.79)* |
| Compensated workers                              | 599              | 15.5     | 1.22 (0.97–1.53) | 1.07 (0.86–1.34) |
| Uncompensated workers                            | 16865            | 13.1     | 1.00         | 1.00            |
| Married                                          |                  |          |             |                 |
| Yes                                              | 17552            | 13.3     | 0.76 (0.55–1.05) | NI               |
| No                                               | 274              | 16.8     | 1.00         |                 |
| Gravidity                                        |                  |          |             |                 |
| Primigravidae                                    | 3885             | 16.5     | 1.50 (1.34–1.67)** | 1.12 (0.99–1.26) |
| Secundigravidae                                  | 5938             | 13.7     | 1.20 (1.09–1.33)** | 1.07 (0.97–1.19) |
| Multigravidae                                    | 8003             | 11.7     | 1.0          | 1.00            |
| History of miscarriage                           |                  |          |             |                 |
| Yes                                              | 394              | 12.2     | 0.90 (0.66–1.22) | NI               |
| No                                               | 17432            | 13.4     | 1.00         |                 |
| History of stillbirth                            |                  |          |             |                 |
| Yes                                              | 100              | 15.0     | 1.14 (0.66–1.98) | NI               |
| No                                               | 17726            | 13.4     | 1.00         |                 |
| Female genital mutilation                        |                  |          |             |                 |
| Yes                                              | 8313             | 12.8     | 0.91 (0.83–0.99)* | 0.92 (0.84–1.01) |
| No                                               | 9513             | 13.9     | 1.00         | 1.0             |
| IPT-SP                                           |                  |          |             |                 |
| Yes                                              | 15716            | 11.2     | 1.00         | 1.00            |
| No                                               | 2110             | 29.8     | 3.38 (3.04–3.76)** | 3.33 (3.00–3.70)** |

IPT-SP: Intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women; OR: Odds ratio; Adj OR: Adjusted odds ratio

*P-value < 0.05

**p-value < 0.001; NI: Not included.

https://doi.org/10.1371/journal.pone.0242368.t003
program [26], has certainly reduced the prevalence of curable bacterial STI such as Chlamydia, as reported for other countries [27]. The results showed a relatively low prevalence of malaria-and curable STI co-infections (1.2%), and so a high cumulated prevalence (27.3%) of both curable infections in pregnant women. These findings from routine data analysis showed that more effort must be done to reduce the prevalence of these curable infections.

For both malaria and STI, younger women (<20 years) and students had the highest prevalence of infection in univariate analysis, but the association did not remain after adjustment with covariates for STI. Several authors have reported a young age as a risk factor of malaria [28–33], and STI [34–36] occurrence. However, some others have not found a statistically significant relationship [37,38]. Young age is known to be a factor of the immaturity of acquired immunity against infections. In addition, the students have a higher level of exposure to mosquito bites due to lessons learning, before going to bed under the mosquito net. It is the same for young women in general, who are more exposed to mosquito bites in the evening because they go to bed later than the older ones. These habits could also explain the higher

Table 4. Factors associated with curable STI detected by symptoms in univariate and multivariate logistic regression analyses in pregnant women.

|                  | n    | STI % | OR (95%CI)          | Adj OR (95%CI) |
|------------------|------|-------|---------------------|----------------|
| **Age in years** |      |       |                     |                |
| < 20             | 3524 | 3.8   | 1.27 (1.00–1.62)*   | 1.14 (0.90–1.46) |
| 20 to 29         | 9279 | 3.3   | 1.12 (0.92–1.36)    | 1.11 (0.91–1.35) |
| ≥30              | 5023 | 3.0   | 1.00                | 1.00           |
| **Occupation**   |      |       |                     |                |
| Students         | 362  | 7.2   | 2.36 (1.58–3.57)**  | 1.93 (1.26–2.95)* |
| Compensated workers | 599 | 5.7   | 1.85 (1.29–2.64)**  | 1.52 (1.07–2.17)* |
| Uncompensated workers | 16865 | 3.2 | 1.00              | 1.00          |
| **Married**      |      |       |                     |                |
| Yes              | 17552| 3.3   | 0.91 (0.48–1.71)    | NI             |
| No               | 274  | 3.7   | 1.00                |                |
| **Gravidity**    |      |       |                     |                |
| Primigravidae    | 3885 | 4.0   | 1.35 (1.10–1.66)*   | 1.19 (0.96–1.49) |
| Secundigravidae  | 5938 | 3.4   | 1.15 (0.95–1.39)    | 1.12 (0.92–1.35) |
| Multigravidae    | 8003 | 3.0   | 1.00                | 1.00           |
| **History of miscarriage** |   | |                 |                |
| Yes              | 394  | 5.3   | 1.66 (1.06–2.60)*   | 1.56 (0.98–2.46) |
| No               | 17432| 3.3   | 1.00                | 1.00           |
| **History of stillbirth** |   | |                 |                |
| Yes              | 100  | 4.0   | 1.21 (0.45–3.31)    | NI             |
| No               | 17726| 3.3   | 1.00                |                |
| **Female genital mutilation** |   | |                 |                |
| Yes              | 8313 | 2.8   | 0.72 (0.61–0.86)**  | 0.76 (0.64–0.90)* |
| No               | 9513 | 3.8   | 1.00                | 1.00           |
| **IPT-SP**       |      |       |                     |                |
| Yes              | 15716| 3.0   | 1.00                | 1.00           |
| No               | 2110 | 6.0   | 2.08 (1.70–2.54)**  | 1.96 (1.60–2.39)** |

STI: Sexually transmitted infections; NI: Not included; Adj OR: Adjusted odds ratio; IPT-SP: Intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women

*p-value < 0.05

**p-value < 0.001.

https://doi.org/10.1371/journal.pone.0242368.t004
proportion of infections in these groups even after adjusting with IPT-SP and other covariates. For STI, young age is also known to be a risk factor due to high sexual behaviour at risk in this age group [21].

Gravidity did not remain statistically associated with malaria or STI after adjusting with other covariates, but a gradient was observed. The women who experienced FGM had fewer STI than those not having. Authors reported psychological psychosexual disorders caused by FGM that could lead to decreased sexual desire [39–41]. In consequence, the sexual experience decrease, and probably the number of partners, so STI risk factors [42]. In addition, other authors reported that the women who have experienced FGM are generally from a conservative family environment that could contribute to reducing these risk factors of STI [43]. Our study found a high proportion of women with FGM (46.6%), which is a notable factor in the low prevalence of STI in a rural setting.

Fig 3. Multivariate odds ratio of coinfection malaria and curable sexually transmitted infections in pregnant women. The red solid vertical line is the reference line. Black dots are the estimated odds ratio. Horizontal black solid lines are 95% confidence intervals. On the right side of the red line, the risk of coinfection increases while it decreases on the left side. An estimate is not significant when its confidence interval crosses the red line. IPT-SP: intermittent preventive treatment with sulfadoxine-pyrimethamine.

https://doi.org/10.1371/journal.pone.0242368.g003
Women who received IPT-SP were more protected against malaria, curable STI, and their coinfections. These findings showed that despite the growing sulfadoxine-pyrimethamine resistance reported by many authors in the last decade [44–47], IPT-SP remained an important strategy for malaria control in Burkina Faso. The proportion of women who received no IPT-SP was still high (11.8%). More effort could be done to get better coverage of pregnant women. The low prevalence of curable STI in women having received SP in prevention is due to the antibacterial property of SP [48,49]. Some authors investigated different preventive ways in adjoining azithromycin to the IPT-SP scheme to reduce these infections [50–52]. Azithromycin could reinforce the action of sulfadoxine-pyrimethamine in malaria prevention [53,54] and could clear asymptomatic STIs that are not routinely diagnosed in health facilities of countries with constrained resource settings [55]. In considering the difficulties to intervene at a young age that was the strongest but non-modifiable factor associated with a high prevalence, this strategy adjoining azithromycin to IPT-SP could be more adapted in the setting of constrained resource to control these infections. Nevertheless, more investigation on this strategy could be done in trials with robust design in several areas with different epidemiological profiles of malaria and STI, to bring more information about their efficacy in the prevention of infections and safety on pregnancy outcomes.

Missing data were important in this study, but there was no evidence against a missing at random hypothesis with a low impact on findings. In addition, the large size of our dataset improved the precision of estimations. The method of diagnosis using syndrome-based algorithms in the routine system can induce a misrepresentation of prevalence of symptomatic STIs and did not allow us to know the etiology of STIs. The RDTs and the microscopy have a low sensitivity that could understate the prevalence of malaria cases. Nevertheless, our results are presenting a good state of reality in malaria and STI management in rural health facilities in Burkina Faso. The large sample in our study cannot exclude that a pregnant woman has been seen twice in ANC. The number of doses of IPT-SP was not used in our study to assess the efficacy of different doses in malaria prevention because of the low reliability of this information due to the women’s references for seeking the best care in another health facility. The sexual subjects are still taboo in the study area, so we have not presented a comparison between the two districts to avoid discrimination between the communities.

Conclusion

Symptomatic malaria and curable STI decreased in the last decade in rural Burkina Faso. These severe and curable infections, known to cause poor outcomes of pregnancy, remain high in rural settings of Burkina Faso, despite implemented control interventions. Their coinfections are also frequent. Pregnant women who received no IPT-SP were the most infected. The IPT-SP is a program implemented in Burkina Faso and that could be improved by the adjunction of azithromycin to reduce adverse pregnancy outcomes related to malaria and curable infections. Young pregnant women under 20 years and students are also more frequently infected. Prevention programs targeting these subgroups of pregnant women could be developed to improve maternal and child health in resource-limited settings.

Supporting information

S1 Table. Factors associated with malarial infection in univariate and multivariate logistic regression analyses in pregnant women using complete cases and available data. (XLSX)
S2 Table. Factors associated with curable STI in univariate and multivariate logistic regression analyses in pregnant women using complete cases and available data.
(XLSX)

S1 Dataset.
(DTA)

Acknowledgments

We would like to thank Nanoro and Yako health district office and all health workers for providing documentation and the best collaboration. We would like also to extend our gratitude to collectors and supervisors of data collection.

Author Contributions

Conceptualization: Serge Henri Zango, Moussa Lingani, Innocent Valea, Ouindpanga Sékou Samadoulougou, Michele Dramaix, Halidou Tinto, Annie Robert.

Formal analysis: Serge Henri Zango.

Funding acquisition: Innocent Valea, Ouindpanga Sékou Samadoulougou, Michele Dramaix, Halidou Tinto, Annie Robert.

Investigation: Serge Henri Zango, Moussa Lingani.

Methodology: Serge Henri Zango, Innocent Valea, Ouindpanga Sékou Samadoulougou, Annie Robert.

Project administration: Phillipe Donnen, Michele Dramaix, Halidou Tinto, Annie Robert.

Supervision: Serge Henri Zango, Moussa Lingani, Innocent Valea, Karim Derra, Phillipe Donnen, Halidou Tinto, Annie Robert.

Validation: Serge Henri Zango, Innocent Valea, Ouindpanga Sékou Samadoulougou, Biebo Bihoun, Toussaint Rouamba, Karim Derra, Eli Rouamba, Phillipe Donnen, Michele Dramaix, Halidou Tinto, Annie Robert.

Writing – original draft: Serge Henri Zango.

Writing – review & editing: Serge Henri Zango, Moussa Lingani, Innocent Valea, Ouindpanga Sékou Samadoulougou, Biebo Bihoun, Toussaint Rouamba, Karim Derra, Eli Rouamba, Phillipe Donnen, Michele Dramaix, Halidou Tinto, Annie Robert.

References

1. Chaponda EB, Matthew Chico R, Bruce J, Michelo C, Vwalika B, Mharakurwa S, et al. Malarial infection and curable sexually transmitted and reproductive tract infections among pregnant women in a rural district of Zambia. Am J Trop Med Hyg. 2016; 95(5):1069–76. https://doi.org/10.4269/ajtmh.16-0370 PMID: 27672205

2. Rowley J, Hoorn V, Korennrimp E, Low N, Unemo M, Abu- LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. 2019;( June):548–62. https://doi.org/10.2471/BLT.18.228486 PMID: 31384073

3. Chico RM, Mayaud P, Arifi C, Mabey D, Ronsmans C, Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: A systematic review. Vol. 307, JAMA—Journal of the American Medical Association. 2012. p. 2079–86. https://doi.org/10.1001/jama.2012.3428 PMID: 22665107

4. Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis Infection in Pregnancy: The Global Challenge of Preventing Adverse Pregnancy and Infant Outcomes in Sub-Saharan Africa and Asia. Biomed Res Int. 2016;2016. https://doi.org/10.1155/2016/9315757 PMID: 27144177
5. Accrombessi M, Fievet N, Yovo E, Cottrell G, Agbotta G, Massougbojdi A, et al. Prevalence and Associated Risk Factors of Malaria in the First Trimester of Pregnancy: A Preconceptional Cohort Study in Benin. J Infect Dis. 2018; 217(9):1309–17. https://doi.org/10.1093/infdis/jiy009 PMID: 29352555

6. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, et al. Adverse effects of falciparum and malaria and the safety of antimalarial treatment in early pregnancy: A population-based study. Lancet Infect Dis. 2012; 12(5):388–96. https://doi.org/10.1016/S1473-3099(11)70339-5 PMID: 22159409

7. Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SEM, Home AW. The role of infection in miscarriage. Hum Reprod Update. 2016; 22(1):116–33. https://doi.org/10.1093/humupd/dmv041 PMID: 26386469

8. World Health Organisation. Guidelines for the treatment of malaria—Third edition. World Health Organization. Geneva, Switzerland; 2015.

9. Scott S, D’Alessandro U, Kendall L, Bradley J, Bojang K, Correa S, et al. Community-based malaria screening and treatment for pregnant women receiving standard intermittent preventive treatment with sulfadoxine-pyrimethamine: A multicenter (the Gambia, Burkina Faso, and Benin) cluster-randomized controlled trial. Clin Infect Dis. 2019; 68(4):586–96. https://doi.org/10.1093/cid/ciy922 PMID: 29961848

10. D’Alessandro U, Hill J, Tarning J, Pll C, Webster J, Gutman J, et al. Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infect Dis. 2018; 18(4):e133–46. https://doi.org/10.1016/S1473-3099(18)30065-3 PMID: 29359998

11. Kattenberg JH, Tahita CM, Versteegh IAJ, Tinto H, Traoré-Coulibaly M, D’Alessandro U, et al. Evaluation of antigen detection tests, microscopy, and polymerase chain reaction for diagnosis of malaria in peripheral blood in asymptomatic pregnant women in Nanoro, Burkina Faso. Am J Trop Med Hyg. 2012; 87(2):251–6. https://doi.org/10.4269/ajtmh.2012.12-0125 PMID: 22593626

12. Langendorf C, Lastrucci C, Sanou-Bicaba I, Blackburn K, Koudika MH, Crucitti T. Dual screen and confirm rapid test does not reduce overtreatment of syphilis in pregnant women living in a non-venerable treponematoses endemic region: A field evaluation among antenatal care attendees in Burkina Faso. Sex Transm Infect. 2018;1–3. https://doi.org/10.1136/sextrans-2018-053722 PMID: 30580325

13. Laga M, Vuylsteke B, Alary M, Gerniers MM, Lebughe JP, Nzila N, et al. Clinical Algorithms for the Screening of Women for Gonococcal and Chlamydial Infection: Evaluation of Pregnant Women and Prostitutes in Zaire. Clin Infect Dis. 1993 Jul 1;17(1):82–8. https://doi.org/10.1093/clinids/17.1.82 PMID: 8353252

14. Daly CC, Wangel AM, Hoffman IF, Canner JK, Lule GS, Lema VM, et al. Validation of the WHO diagnostic algorithm and development of an alternative scoring system for the management of women presenting with vaginal discharge in Malawi. Sex Transm Infect. 1998 Jun 1;74(SUPPL. 1).

15. Mayaud P, Ka-Gina G, Cornelissen J, Todd J, Latiano G, West B, et al. Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. Sex Transm Infect [Internet]. 1998 [cited 2020 Sep 14]; 74(SUPPL. 1):S77–84. Available from: https://pubmed.ncbi.nlm.nih.gov/10023356/. PMID: 10023356

16. Valea I, Tinto H, Drabo MK, Huysregts L, Sorgo H, Ouedraogo JB, et al. An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anemia and perinatal mortality in Burkina Faso. Malar J. 2012; 11(1):71. https://doi.org/10.1186/1475-2875-11-71 PMID: 22433778

17. Kirakoya-Samadoulouguou F, Defer MC, Yaro S, Fao P, Ilboudo F, Langani Y, et al. Low seroprevalence of syphilis in Burkina Faso. Sex Transm Infect. 2011; 87(1):35–7. https://doi.org/10.1136/sti.2010.042465 PMID: 20693149

18. Roberts SA, Brabin L, Diallo S, Gies S, Nelson A, Stewart C, et al. Mucosal lactoferrin response to genital tract infections is associated with iron and nutritional biomarkers in young Burkinabé women. Eur J Clin Nutr. 2019; 73(11):1464–72. https://doi.org/10.1002/ajcn.14115 PMID: 31168085

19. INSD. Annuaire Statistique 2017. Direction générale des études et des statistiques sectorielles. 2018. [Cited 2019 July 9] Available from: http://www.insd.bf/n/index.php/publications?id=36.

20. Rouamba T, Nakanabo-Diallo S, Derra K, Rouamba E, Kasenga A, Inoue Y, et al. Socioeconomic and environmental factors associated with malaria hotspots in the Nanoro demographic surveillance area, Burkina Faso. BMC Public Health. 2019; 19(1):1–14. https://doi.org/10.1186/s12889-018-6344-7 PMID: 30606151

21. World Health Organisation. Global strategy for the Prevention and Control of Sexually Transmitted: 2006–2015: breaking the chain of transmission. Geneva, Switzerland; 2007.

22. World Health Organisation. World Malaria Report 2018. Geneva, Switzerland; 2018. [Cited 2019 July 9] Available from: https://www.who.int/malaria/publications/world-malaria-report-2018/en/.

23. Zemouri C, Wi TE, Kiarie J, Seuc A, Mogasale V, Latif A, et al. The performance of the vaginal discharge syndromic management in treating vaginal and cervical infection: A systematic review and
24. Vuylsteke B, Laga M, Alary M, Gerniers M-M, Lebughe J-P, Nzila N, et al. Clinical Algorithms for the Screening of Women for Gonococcal and Chlamydial Infection: Evaluation of Pregnant Women and Prostitutes in Zaire. Clin Infect Dis. 1993 Jul 1; 17(1):82–8. https://doi.org/10.1093/clinids/17.1.82 PMID: 8353252

25. Van der Eem L, Dubbink JH, Struthers HE, McIntyre JA, Ouburg S, Morré SA, et al. Evaluation of syndromic management guidelines for treatment of sexually transmitted infections in South African women. Trop Med Int Heal. 2016; 21(9):1138–46. https://doi.org/10.1111/tmi.12742 PMID: 27350659

26. Koukounari A, Touré S, Donnelly CA, Ouedraogo A, Yoda B, Ky C, et al. Integrated monitoring and evaluation and environmental risk factors for urogenital schistosomiasis and active trachoma in Burkina Faso before preventative chemotherapy using sentinel sites. BMC Infect Dis. 2011; 11(1):191. https://doi.org/10.1186/1471-2334-11-191 PMID: 21749703

27. Marks M, Bottomley C, Tome H, Pitakaka R, Butcher R, Sokana O, et al. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands. Sex Transm Infect. 2016; 92(4):261–5. https://doi.org/10.1136/sextrans-2015-052439 PMID: 26888658

28. Anchang-Kimbi JK, Nkweti VN, Ntonifor HN, Apinjoh TO, Tata RB, Chi HF, et al. Plasmodium falciparum parasitaemia and malaria among pregnant women at first clinic visit in the mount Cameroon Area. BMC Infect Dis. 2015; 15(1):1–10. https://doi.org/10.1186/s12879-015-1211-6 PMID: 26494140

29. Mbu RE, Takang WA, Fouelifack FY, Tumasang FN, Tonye R. Clinical malaria among pregnant women on combined insecticide treated nets (ITNs) and intermittent preventive treatment (IPTp) with sulphadoxine-pyrimethamine in Yaounde, Cameroon. BMC Womens Health. 2014; 14(1):1–6.

30. Lufele E, Umbers A, Ordi J, Ome-Kaius M, Wangnapi R, Unger H, et al. Risk factors and pregnancy outcomes associated with placental malaria in a prospective cohort of Papua New Guinean women. Malar J. 2017; 16(1):427. https://doi.org/10.1186/s12936-017-2077-4 PMID: 29065884

31. Ndeserua R, Juma A, Mosha D, Chilongola J. Risk factors for placental malaria and associated adverse pregnancy outcomes in Rulifi, Tanzania: A hospital based cross sectional study. Afr Health Sci. 2015; 15(3):810–8. https://doi.org/10.4314/aha.v15i3.15 PMID: 26957969

32. Fana SA, Bunza MDA, Anka SA, Imam AU, Nataa SU. Prevalence and risk factors associated with malaria infection among pregnant women in a semi-urban community of north-western Nigeria. Infect Dis Poverty. 2015; 4(1):24.

33. World Health Organisation. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. Overview and Estimates. World Health Organization. Geneva, Switzerland; 2001. [Cited 2019 July 9] Available from: https://www.who.int/reproductivehealth/publications/rtis/HIV_AIDS_2001_2/en/.

34. Cisse M, Sangare I, Lougue G, Bamba S, Bayane D, Guiguemde RT. Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. Overview and Estimates. World Health Organization. Geneva, Switzerland; 2001. [Cited 2019 July 9] Available from: https://www.who.int/reproductivehealth/publications/rtis/HIV_AIDS_2001_2/en/.

35. Cisse M, Sangare I, Lougue G, Bamba S, Bayane D, Guiguemde RT. Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. Overview and Estimates. World Health Organization. Geneva, Switzerland; 2001. [Cited 2019 July 9] Available from: https://www.who.int/reproductivehealth/publications/rtis/HIV_AIDS_2001_2/en/.

36. Cisse M, Sangare I, Lougue G, Bamba S, Bayane D, Guiguemde RT. Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. Overview and Estimates. World Health Organization. Geneva, Switzerland; 2001. [Cited 2019 July 9] Available from: https://www.who.int/reproductivehealth/publications/rtis/HIV_AIDS_2001_2/en/.

37. Cisse M, Sangare I, Lougue G, Bamba S, Bayane D, Guiguemde RT. Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. Overview and Estimates. World Health Organization. Geneva, Switzerland; 2001. [Cited 2019 July 9] Available from: https://www.who.int/reproductivehealth/publications/rtis/HIV_AIDS_2001_2/en/.

38. Adam I, Khamis AH, Elbashir MI. Prevalence and risk factors for Plasmodium falciparum malaria in pregnant women attending antenatal clinic in Bobo-Dioulasso (Burkina Faso). BMC Infect Dis. 2014; 14(1):1–7. https://doi.org/10.1186/s12879-014-0631-z PMID: 25408152

39. Oyefara J. Ritual Female Genital Mutilation: A Psychosocial Analysis of a Flourishing Rather than a Dying Tradition in Oworonshoki Community, Lagos, Nigeria. IFE Psychol. 2014; 22:72–83.

40. Chibber R, El-salah E, El-harmi J. Female circumcision: obstetrical and psychological sequelae continues unabated in the 21st century. J Matern Neonatal Med. 2011 Jun; 24(6):833–6. https://doi.org/10.3109/14767058.2010.531318 PMID: 21121711
41. Klein E, Helzner E, Shayowitz M, Kohlhoff S, Smith-Norowitz TA. Female Genital Mutilation: Health Consequences and Complications—A Short Literature Review. Obstet Gynecol Int. 2018; 2018. https://doi.org/10.1155/2018/7365715 PMID: 30116269

42. Navarro-Cremades F, Palazón-Brus A, Marhuenda-Amorós D, Tomás-Rodríguez Ml, Antóñ-Ruiz F, Belda-Ibañez J, et al. Sexual behaviour and risk of sexually transmitted infections in young female healthcare students in Spain. PeerJ. 2016; 2016(2):1–15. https://doi.org/10.7717/peerj.1699 PMID: 26966654

43. Khodary Y, Hamdy N. FGM in Egypt between socio-cultural barriers and lack of political will. J Aggress Confl Peace Res. 2019; 11(4):252–62.

44. Kajubi R, Ochieng T, Kakuru A, Jagannathan P, Nakalembe M, Ruel T, et al. Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. Lancet. 2019; 393(10179):1428–39.

45. Capan M, Mombo-Ngoma G, Makristathis A, Ramharter M. Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: Comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin. Malar J. 2010; 9(1):303.

46. Ruizendaal E, Tahita MC, Geskus RB, Versteeg I, Scott S, D’Alessandro U, et al. Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso. Malar J. 2017; 16(1):1–15. https://doi.org/10.1186/s12936-016-1650-6 PMID: 28049519

47. Tagbor H, Cairns M, Bojang K, Coulibaly SO, Kayentao K, Williams J, et al. A non-inferiority, individually randomized trial of intermittent screening and treatment versus intermittent preventive treatment in the control of malaria in pregnancy. PLoS One. 2015; 10(8):1–17.

48. Chico RM, Chaponda EB, Ariri C, Chandramohan D. Sulfadoxine-pyrimethamine exhibits dose-response protection against adverse birth outcomes related to malaria and sexually transmitted and reproductive tract infections. Clin Infect Dis. 2017; 64(8):1043–51. https://doi.org/10.1093/cid/cix026 PMID: 28328383

49. Chico RM, Moss WJ. Prevention of malaria in pregnancy: A fork in the road? Vol. 386, The Lancet. 2015. p. 2454–6.

50. Chico RM, Chandramohan D. Azithromycin plus chloroquine: Combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011; 7(9):1153–67. https://doi.org/10.1517/17425255.2011.598506 PMID: 21736423

51. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: A randomized controlled trial. Am J Trop Med Hyg. 2010; 83(6):1212–20.

52. Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CSNLW, et al. Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: A randomised controlled trial. BMC Med. 2015; 13(1):1–16.

53. van Eijk A, Terlouw DJ. Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev. 2007;(3).

54. Moore BR, Benjamin JM, Auyeung SO, Salman S, Yadi G, Griffin S, et al. Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol. 2016;199–212. https://doi.org/10.1111/bcp.12910 PMID: 26889763

55. Kallianl I, Molfo I, Chaponda M, Rogerson SJ, Alker AP, Kwiek JJ, et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One. 2007; 2(11).